The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
NeoImmuneTech
Neonc Technologies, Inc.
ImmunityBio, Inc.
VM Oncology, LLC
Merck Sharp & Dohme LLC
Seagen Inc.
Sotio Biotech Inc.
Carisma Therapeutics Inc
Sellas Life Sciences Group
Salubris Biotherapeutics Inc
University of Florida
Fate Therapeutics
Xencor, Inc.
Incyte Corporation
MultiVir, Inc.
Incyte Corporation
Western Regional Medical Center